What were the key findings of the 2025 study on sacubitril/valsartan in resistant hypertension?

The 2025 study found that up to 77% of patients achieved target blood pressure levels with sacubitril/valsartan. But it also revealed growing rates of adverse events like kidney injury and electrolyte disturbances over the one-year follow-up period.

How do experts view the use of sacubitril/valsartan for resistant hypertension?

Key opinion leaders have emphasized that "close monitoring is critical" when using sacubitril/valsartan, as not all patients will be able to tolerate the safety risks. They have called for more real-world insight to better understand which resistant hypertension patients can benefit most from the treatment.

Home / Health / Sacubitril/Valsartan Offers Promise, But Risks, for Resistant Hypertension

Sacubitril/Valsartan Offers Promise, But Risks, for Resistant Hypertension

Q: What is the role of sacubitril/valsartan in treating resistant hypertension?

Sacubitril/valsartan has shown promise as a late-line therapy for resistant hypertension, with the 2025 study finding it can effectively lower blood pressure in these patients. However, the treatment also carries significant safety risks that require close monitoring.

11 Nov

•

Summary

Sacubitril/valsartan improves blood pressure control in resistant hypertension
Significant adverse events like kidney injury and electrolyte disturbances observed
Need for close monitoring and patient selection emphasized by experts

Sacubitril/Valsartan Offers Promise, But Risks, for Resistant Hypertension

In November 2025, at the American Heart Association Scientific Sessions in New Orleans, researchers presented findings from a real-world study on the use of sacubitril/valsartan in treating resistant hypertension. The retrospective study, which tracked over 2,000 adults across the US, Middle East, and Europe, revealed that the proportion of patients achieving target blood pressure levels steadily increased over the one-year follow-up, reaching up to 77%.

However, the study also uncovered significant and growing rates of adverse events, including acute kidney injury, electrolyte disturbances, and all-cause hospitalizations. Key opinion leaders emphasized that "close monitoring is critical, as not all patients will tolerate the risks" associated with sacubitril/valsartan.